# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-047833
Filing Date
2024-04-25
Accepted
2024-04-24 20:42:21
Documents
54
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | vktx-20240331.htm iXBRL | 10-Q | 1752016
2 | EX-31.1 | vktx-ex31_1.htm | EX-31.1 | 15703
3 | EX-31.2 | vktx-ex31_2.htm | EX-31.2 | 15679
4 | EX-32.1 | vktx-ex32_1.htm | EX-32.1 | 11775
| Complete submission text file | 0000950170-24-047833.txt |  | 7279387

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | vktx-20240331.xsd | EX-101.SCH | 991660
57 | EXTRACTED XBRL INSTANCE DOCUMENT | vktx-20240331_htm.xml | XML | 1242871

Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37355 | Film No.: 24872473
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)